Tata Chemicals Limited has announced significant changes in its senior management personnel structure, effective February 1, 2026. The company made this disclosure on January 14, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Leadership Transitions

The management restructuring involves multiple senior positions across the organization. The changes reflect both planned retirements and strategic appointments to strengthen the company's leadership team.

Succession Planning and Strategic Appointments

The most significant transition involves the Chief Commercial Officer position. K. R. Venkatadri, the current Chief Commercial Officer, will superannuate on March 31, 2026, following the company's retirement policy. To ensure smooth transition, Alok Chandra, currently serving as Chief – HSE, has been designated as Chief Commercial Officer (Designate) effective February 1, 2026, and will formally assume the Chief Commercial Officer role from April 1, 2026.

New Leadership Roles

The company has created two new senior management positions to enhance its operational capabilities. Narasimha V. Kamath will take on the role of Chief Safety, Sustainability & Manufacturing Officer (CSSMO), while Rajesh Kamat will serve as Chief Strategy & Projects Officer (CSPO). Both appointments are effective from February 1, 2026.

Regulatory Compliance

The announcement was made through a formal communication to both BSE Limited and National Stock Exchange of India Limited. The disclosure was signed by Company Secretary Jeraz E. Mahernosh and submitted in accordance with SEBI Master Circular dated November 11, 2024. The company's scrip code on BSE is 500770, while its symbol on NSE is TATACHEM.

These management changes represent Tata Chemicals' commitment to maintaining strong leadership continuity while adapting its organizational structure to meet evolving business requirements.

Tata Chemicals announced that its wholly-owned subsidiary, Tata Chemicals International Pte. Limited (TCIPL), has executed a Share Purchase Agreement to acquire 100% equity stake in Novabay Pte. Limited, a Singapore-based premium sodium bicarbonate manufacturer. The acquisition has been confirmed at an enterprise value of EUR 25.00 million.

Strategic Acquisition Details

The acquisition parameters demonstrate the strategic nature of this transaction:

Novabay operates with an issued and paid-up share capital of US$ 35,532,140.00, comprising 3,553,214 ordinary shares of US$ 10.00 each. The company recorded a turnover of SGD 29.49 million, positioning it as a significant player in the premium sodium bicarbonate market.

Business Profile and Market Position

Novabay, incorporated in November 2015, is primarily engaged in manufacturing and selling premium-grade sodium bicarbonate. The company serves diverse sectors including pharmaceutical, food, personal care, cosmetics, environmental water treatment, and chemical industries across multiple geographic regions.

The company is recognized as among the largest premium sodium bicarbonate producers in the Asia-Pacific region, excluding China. Its fully automated facility holds key certifications including cGMP and API, supporting its position in high-value pharmaceutical and personal care applications.

Strategic Rationale and Market Dynamics

The Managing Director and CEO of Tata Chemicals emphasized that Novabay's focus on premium-grade sodium bicarbonate aligns seamlessly with the company's strategy to expand presence in high-value, non-cyclical product segments. This acquisition strengthens Tata Chemicals' capabilities in specialty bicarbonate markets and enhances ability to serve premium customer requirements.

The premium-grade sodium bicarbonate market benefits from steady demand drivers including rising haemodialysis needs in healthcare sector, improved access to medical care globally, growing consumption in emerging markets, and expanding applications in personal care and food sectors.

Corporate Structure and Compliance

Post-completion, Novabay will become a 100% subsidiary of TCIPL, which is itself a wholly-owned subsidiary of Tata Chemicals Limited. The proposed acquisition does not fall within related party transactions, and the promoter/promoter group/group companies have no existing interest in Novabay.

The acquisition price is subject to customary adjustments for net debt, net working capital, and other standard commercial terms. No governmental or regulatory approvals are required for completing this transaction.

Growth Potential and Value Creation

With current production capacity of approximately 60,000 tons and potential expansion to 100,000 tons, Novabay offers significant growth opportunities. The company's established market presence, technical certifications, and automated manufacturing capabilities position it well for capturing increasing demand in premium sodium bicarbonate applications. This strategic acquisition is expected to accelerate Tata Chemicals' long-term growth and value creation objectives while strengthening its portfolio in specialty chemicals and premium-grade products serving non-cyclical end markets.